New Findings Provide Additional Insights into the Management of Anaemia and Secondary Hyperparathyroidism in Chronic Kidney Disease Patients.

PR Newswire Europe, May, 2009

MILAN, May 25 /PRNewswire/ --

Data presented from large-scale observational studies provide new insights into the day-to-day management of two major complications of CKD: anaemia and secondary hyperparathyroidism (SHPT).(1), (2), (3), (4)

 
 
    - CKD anaemia: Aranesp(R) (darbepoetin alfa) flexible dosing intervals 
      help maintain haemoglobin (Hb) levels within the target range for 
      dialysis and pre-dialysis patients, while offering the convenience of 
      extended dosing(1), (2), (3) 
 
    - SHPT: New European data show the importance of early initiation of 
      Mimpara(R) (cinacalcet) to achieve therapeutic targets in SHPT(4) 
 

A nephrology pioneer for more than 20 years, Amgen presented at the World Congress of Nephrology...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement